Photo of Oladapo Yeku,  MD, PhD, FACP

Oladapo Yeku, MD, PhD, FACP

Massachusetts General Hospital

Massachusetts General Hospital
Phone: (617) 643-9354


oyeku@mgh.harvard.edu

Oladapo Yeku, MD, PhD, FACP

Massachusetts General Hospital

EDUCATIONAL TITLES

  • Instructor, Medicine, Harvard Medical School
  • Clinical Assistant in Medicine, Medicine, Massachusetts General Hospital

DF/HCC PROGRAM AFFILIATION

Research Abstract

Dr. Yeku’s research involves characterizing the suppressive tumor microenvironment and evaluating strategies to improve the efficacy of novel immunotherapeutic approaches for the management of gynecologic malignancies. This includes immune checkpoint inhibitors, antibody-drug conjugates, bispecific T-cell engager therapy, and adoptive cellular therapy, including CAR-T cells. His research involves the use of relevant cell lines, preclinical animal models, and clinical trials. Dr. Yeku has published on the role of the immunosuppressive tumor microenvironment in ovarian cancer, in addition to devising cell engineering approaches to overcoming this challenge. His research builds on his expertise as a physician scientist focusing exclusively on Gynecologic Medical Oncology. He sees patients in clinic, performs translational research, and runs clinical trials ranging from phase 1 to randomized phase 3 studies. His affiliation with the MGH phase 1/Developmental therapeutics clinic and the cellular therapeutics group allows him a platform to translate his laboratory findings to clinical trials.

Publications

Powered by Harvard Catalyst
  • Yeku O, Russo AL, Lee H, Spriggs D. A phase 2 study of combined chemo-immunotherapy with cisplatin-pembrolizumab and radiation for unresectable vulvar squamous cell carcinoma. J Transl Med 2020; 18:350. PubMed
  • Ramos A, Del Carmen M, Yeku O. PD-1 Inhibitor Therapy in a Patient with Preexisting P-ANCA Vasculitis: A Case Report and Review of the Literature. Case Rep Oncol Med 2020; 2020:3428945. PubMed
  • Zhao Y, Cao J, Melamed A, Worley M, Gockley A, Jones D, Nia HT, Zhang Y, Stylianopoulos T, Kumar AS, Mpekris F, Datta M, Sun Y, Wu L, Gao X, Yeku O, Del Carmen MG, Spriggs DR, Jain RK, Xu L. Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma. Proc Natl Acad Sci U S A 2019; 116:2210-2219. PubMed
  • Avanzi MP, Yeku O, Li X, Wijewarnasuriya DP, van Leeuwen DG, Cheung K, Park H, Purdon TJ, Daniyan AF, Spitzer MH, Brentjens RJ. Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System. Cell Rep 2019; 23:2130-2141. PubMed
  • Rafiq S, Yeku OO, Jackson HJ, Purdon TJ, van Leeuwen DG, Drakes DJ, Song M, Miele MM, Li Z, Wang P, Yan S, Xiang J, Ma X, Seshan VE, Hendrickson RC, Liu C, Brentjens RJ. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol 2019; 36:847-856. PubMed
  • Yeku O, Li X, Brentjens RJ. Adoptive T-Cell Therapy for Solid Tumors. Am Soc Clin Oncol Educ Book 2019; 37:193-204. PubMed
  • Yeku OO, Purdon TJ, Koneru M, Spriggs D, Brentjens RJ. Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment. Sci Rep 2019; 7:10541. PubMed
  • Yeku O, Slovin SF. Radium-223 and concomitant therapies: prospects and prudence. Transl Androl Urol 2019; 5:968-970. PubMed
  • Yeku OO, Brentjens RJ. Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy. Biochem Soc Trans 2018; 44:412-8. PubMed
  • Yeku O, Slovin SF. Metabolism and pharmacokinetics of radium-223 in prostate cancer. Expert Opin Drug Metab Toxicol 2018; 11:843-9. PubMed
  • Tarhini AA, Lin Y, Yeku O, LaFramboise WA, Ashraf M, Sander C, Lee S, Kirkwood JM. A four-marker signature of TNF-RII, TGF-α, TIMP-1 and CRP is prognostic of worse survival in high-risk surgically resected melanoma. J Transl Med 2018; 12:19. PubMed
  • Ali H, Yeku O, Giesler D, Campbell-Massa R, Gao F, Amjad AI. Breast Mass and Lytic Bone Lesions: A Rare Presentation of Non-Hodgkin's Lymphoma Arising in the Breast. Case Rep Oncol Med 2018; 2013:547171. PubMed
  • Huang P, Yeku O, Zong H, Tsang P, Su W, Yu X, Teng S, Osisami M, Kanaho Y, Pessin JE, Frohman MA. Phosphatidylinositol-4-phosphate-5-kinase alpha deficiency alters dynamics of glucose-stimulated insulin release to improve glucohomeostasis and decrease obesity in mice. Diabetes 2018; 60:454-63. PubMed
  • Yeku O, Frohman MA. Rapid amplification of cDNA ends (RACE). Methods Mol Biol 2016; 703:107-22. PubMed
  • Dall'Armi C, Hurtado-Lorenzo A, Tian H, Morel E, Nezu A, Chan RB, Yu WH, Robinson KS, Yeku O, Small SA, Duff K, Frohman MA, Wenk MR, Yamamoto A, Di Paolo G. The phospholipase D1 pathway modulates macroautophagy. Nat Commun 2018; 1:142. PubMed
  • Su W, Yeku O, Olepu S, Genna A, Park JS, Ren H, Du G, Gelb MH, Morris AJ, Frohman MA. 5-Fluoro-2-indolyl des-chlorohalopemide (FIPI), a phospholipase D pharmacological inhibitor that alters cell spreading and inhibits chemotaxis. Mol Pharmacol 2018; 75:437-46. PubMed
  • Yeku O, Scotto-Lavino E, Frohman MA. Identification of alternative transcripts using rapid amplification of cDNA ends (RACE). Methods Mol Biol 2016; 590:279-94. PubMed
  • Yeku O, Slovin SF. Immune Therapy for Prostate Cancer. Cancer J 2019; 22:334-341. PubMed
Hide